Alexis Liakos

Alexis Liakos

Auto-generated profile, based on publicly available information

Alexis Liakos

Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
TATejas S Athni
Tejas S Athni
CSCarolyn B Strauch
Carolyn B Strauch
VKVictor Kovac
Victor Kovac
EAEsther Arbona-Haddad
Esther Arbona-Haddad
IVInia Perez Villa
Inia Perez Villa
ASAmy C Sherman
Amy C Sherman
Background: Invasive fungal sinusitis (IFS) profoundly impacts individuals with hematological malignancies, with rapid progression and high mortality rates. In an evolving therapeutic landscape, outcomes for patients with hematological malignancies who develop IFS warrant further evaluation. Methods: We performed a descriptive case series and retrospective review of patients with hematologic malignancies who developed proven IFS (per European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria) between 2005 and 2024 at a tertiary academic center. Clinical data and outcomes were collected from electronic medical records. Statistical analyses included Fisher exact tests, t tests, or Wilcoxon rank-sum tests. Kaplan-Meier curves were used to estimate survival probability, and log-rank tests were compared across groups. Results: Thirty-one patients with confirmed IFS were identified. Most patients had acute myeloid leukemia (61.3%) and received cytotoxic chemotherapy (96.8%). Targeted oncologic therapies included BCL2 inhibitors (29.0%), FLT3 inhibitors (19.4%), antibody-based therapies (12.9%), BTK inhibitors (6.4%), and antibody–drug conjugates (6.4%). The most common fungal isolates were Aspergillus (22.6%), Fusarium (16.1%), and Rhizopus (9.7%). Amphotericin B (96.8%) and voriconazole (71.0%) were frequently used, and newer antifungals included isavuconazole (38.7%), olorofim (3.3%), and fosmanogepix (3.3%). Necrotic tissue (45.2%) and mucosal thickening (87.1%) were common on sinonasal endoscopy and computed tomography scan, respectively. Orbital (25.8%) and intracranial (9.7%) extension occurred in a minority. Most patients underwent functional endoscopic sinus surgery (80.6%). Serum fungal biomarkers were infrequently positive, with (1,3)-ß-D-glucan in 19.4% and galactomannan in 9.7%. Overall mortality was 71.0% at the end of the study period, with a median survival (interquartile range) of 101 (21–299) days. Mortality was 22.6% at 1 month, 25.8% at 2 months, 32.3% at 3 months, 41.9% at 6 months, 54.8% at 1 year, 58.1% at 2 years, and 64.5% at 3 years. Conclusions: Despite novel therapies and aggressive surgical interventions, patients with IFS had high mortality.

28 April 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
VKVictor Kovac
Victor Kovac
SHSarah P Hammond
Sarah P Hammond
NINicolas C Issa
Nicolas C Issa
ALAlexis Liakos
Alexis Liakos
JLJessica S Little
Jessica S Little
AWAnn E Woolley
Ann E Woolley
Invasive fusariosis (IF) is a rare but aggressive infection seen in immunocompromised patients that often exhibits elevated minimum inhibitory concentrations (MICs) to antifungal drugs, making the optimal therapeutic remains unknown. We identified all cases of IF between January 2015 and April 2024 and collected patient characteristics, including clinical presentation, therapy, and 12-week outcomes, as well as organism species identification and susceptibility testing. Twenty-one patients were diagnosed with either proven (n = 14) or probable (n = 7) IF. The mean age was 60 years and 71% were male. Hosts had hematologic disorders in 71% of which 80% had acute leukemia. Seventy-three percent were neutropenic at the time of IF diagnosis and 40% had received allogeneic stem cell transplantation. Infections were localized in 57% and disseminated in 43%. Skin was the most common site of involvement (67%), followed by pulmonary (42%) and sinus (21%). The most common species was Fusarium solani complex (38%). Susceptibility testing was performed on 81% of isolates. MICs were ≥4 µg/mL for mold-active triazoles in 94% and ≥1 µg/mL for terbinafine in 65%. The most common definitive regimens were a triazole plus terbinafine (62%) and triazole monotherapy (19%). Surgical debridement was performed in 52%. Seventy-six percent of patients survived to 12 weeks. Fifty-seven percent achieved complete responses, 29% partial responses, and 14% failed to respond to therapy at 12 weeks. Mortality in patients with IF is high. Despite elevated MICs, clinical responses to triazole antifungals with or without the addition of terbinafine are observed.

26 September 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
SGSimran Gupta
Simran Gupta
TATejas S Athni
Tejas S Athni
EAEsther Arbona-Haddad
Esther Arbona-Haddad
IVInia Perez Villa
Inia Perez Villa
ALAlexis Liakos
Alexis Liakos
ASAmy C Sherman
Amy C Sherman
Among 132 people with hematologic malignancies and invasive fungal disease, invasive fungal sinusitis was associated with greater dissemination, lower biomarker sensitivity, more diverse fungal pathogens, and higher rates of chronic rhinosinusitis and sinonasal defects than invasive fungal pneumonia. These findings suggest distinct clinical syndromes with different risk factors and diagnostic considerations.